eXoZymes Named B2i Digital Featured Company With Cell-Free AI Enzyme Platform

B2i Digital has announced that eXoZymes Inc. has been named a B2i Digital Featured Company, highlighting the company's cell-free, AI-guided enzyme platform that provides partners with access to design and run enzyme pathways for target chemical production. This technology represents a scalable, lower-impact alternative to traditional petrochemical processes, natural extraction methods, and conventional synthetic biology approaches. The platform specifically addresses the scale-up bottleneck that has challenged first-generation synthetic biology implementations, offering what company leadership describes as a timely solution for investors focused on sustainable industrial biotechnology.

David Shapiro, CEO of B2i Digital, emphasized the significance of this partnership, noting that eXoZymes' technology targets critical limitations in existing biomanufacturing systems. The platform aims to replace selected petrochemical processes with more sustainable biosolutions, positioning the company at the forefront of what industry leaders are calling the fourth industrial revolution at the intersection of biology and technology. Michael Heltzen, CEO of eXoZymes, stated that the collaboration with B2i Digital will enhance the company's visibility among investors who understand the value of their scalable enzyme-based approach as an alternative to traditional manufacturing methods.

The eXoZymes platform represents what the company describes as a historic first in biomanufacturing by freeing enzyme-driven chemical reactions from cellular limitations. The company's advanced enzymes, called exozymes, are enhanced through artificial intelligence and bioengineering to function effectively in bioreactors without requiring living cells. This innovation enables the transformation of biomass into essential natural products, medicines, chemicals, and biofuels through a commercially viable path to scalable and sustainable production of small molecules at industrial scale. The technology initially targets low volume, high value natural products with potential pharmaceutical applications, offering partners a pathway to upgrade traditional petrochemical production methods with more sustainable alternatives.

B2i Digital partners with leading investor conferences, public companies, and capital markets advisors through its Featured Conference, Featured Company, and Featured Expert programs. The firm's proprietary network includes over 1.4 million market participants, and its approach blends digital marketing technology with capital markets expertise to deliver institutional-quality exposure for growth companies. Additional information about B2i Digital can be found at https://b2idigital.com. eXoZymes has developed its biomanufacturing platform to provide tools and insights for designing, engineering, controlling, and optimizing natural processes to produce chemical compounds, with more details available at https://exozymes.com.